25 October 2024
IXICO PLC
("IXICO" or
the "Company")
Result of General Meeting,
Issue of Equity and Total Voting Rights
IXICO plc (AIM: IXI), the medical
imaging advanced analytics company delivering insights in
neuroscience, announces that all resolutions put to Shareholders at
the General Meeting held earlier today in connection with the
placing, subscription and retail offer announced by the Company on
8 October 2024 were duly passed, including the amendment
resolutions referred to in the announcement dated 22 October
2024.
|
Resolution
|
For
|
Against
|
Withheld
|
Total votes
cast
|
|
|
|
Number of
votes
|
%
|
Number of
votes
|
%
|
Number of
votes
|
|
|
1
|
Ordinary resolution to authorise the
directors to allot shares
|
26,857,594
|
99.97%
|
8,194
|
0.03%
|
37,912
|
26,865,788
|
|
2
|
Ordinary resolution to approve the
Company's EMI Share Option Plan
|
26,676,840
|
99.30%
|
188,448
|
0.70%
|
38,412
|
26,865,288
|
|
3
|
Special resolution to authorise the
directors to disapply pre-emption rights
|
26,827,687
|
99.86%
|
38,101
|
0.14%
|
37,912
|
26,865,788
|
(1) Any
proxy appointments, which gave discretion to the Chairman have been
included in the "For" votes total.
(2) Votes
"For" and "Against" any resolution are expressed as a percentage of
votes validly cast for that resolution.
(3) A vote
"Withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against",
nor in the aggregate figure of total votes cast.
Issue of Equity and Total Voting Rights
Following shareholder approval at
the general meeting and conditional on admission, 41,315,792 new
ordinary shares have been allotted pursuant to the Placing, 516,244
new ordinary shares pursuant to the Retail Offer and 789,472
pursuant to the Subscription.
The Company has therefore allotted a
total of 42,621,508 new ordinary shares in connection with the
Fundraising.
Admission is expected to take place
at 8.00 a.m. on or around 28 October 2024.
Following Admission, the total
number of Ordinary Shares in the capital of the Company in issue
will be 92,668,598 with each Ordinary Share carrying the right to
one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the
Company will be 92,668,598.
The above figure may be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure, Guidance and Transparency
Rules.
Capitalised terms used in this
announcement have the meaning given to them in the announcement of
the Placing and Subscription dated 8 October 2024, unless otherwise
defined in this announcement.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan
Hodkinson (Corporate
Finance)
|
|
|
Nigel Birks (Life Sciences
Specialist Sales)
|
|
|
Harriet Ward (Corporate
Broking)
|
|
|
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on X
(formerly Twitter) @IXICOnews
